ARCHIVES

FDA Rile Changes Reporting Requirements for Adverse Events

This article is from The Cancer Letter archive.

Vol. 20 No. 44 | November 18, 1994

Download PDF Visit The Full Archive

Related Articles

Examples Of CCOP Cancer Control Projects Listed

May 16, 1986

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

April 25, 2014

NCI, FDA Near Agreement On INDs; Young, Hoogstraten Clash On Rubidazone

January 14, 1977

HCFA Abadons Plan To Cut Cancer Drug Payments.

September 15, 2000

Mytomycin C, RT Improve Head & Neck Results, Sartorelli Reports; Other AACR, ASCO Lectures

June 5, 1987

Mammography For Women Under 50 Debated; Cut Of 3-4% Offered As Budget Trimmer

July 23, 1976